WSGR logoWSGR logo
Taylor Miller
Associate
Corporate
Boston

D617-598-7841

Download vCard
Open PDF

Taylor Miller is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is part of the firm's corporate practice. Taylor represents life sciences and technology companies throughout their business life cycle, including with respect to matters of formation, venture capital financings, and corporate governance.

Taylor was a summer associate in Wilson Sonsini's Boston office, where she assisted with the representation of early-stage life sciences companies.

Experience

Taylor Miller is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is part of the firm's corporate practice. Taylor represents life sciences and technology companies throughout their business life cycle, including with respect to matters of formation, venture capital financings, and corporate governance.

Taylor was a summer associate in Wilson Sonsini's Boston office, where she assisted with the representation of early-stage life sciences companies.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Learn More
Client Highlights
Wilson Sonsini Advises Aqtual on $31 Million Series B
On July 10, 2025, Aqtual, a Hayward, California-based precision medicine company, announced the closing of its $31 million Series B financing round. Investors in the oversubscribed round included Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.